Literature DB >> 3537646

Hypothesis: AIDS encephalopathy is due to primary and persistent infection of the brain with a human retrovirus of the lentivirus subfamily.

L G Epstein, L R Sharer, D C Gajdusek.   

Abstract

Recent evidence has demonstrated that human T-lymphotropic retroviruses are present in the brain of patients with acquired immunodeficiency syndrome (AIDS). Studies by neuropathological, ultrastructural and nucleic acid hybridization techniques indicate that these human retroviruses are neurotropic as well as lymphotropic. Striking similarities to the animal retroviruses of the lentivirus subfamily provide a rationale to implicate these human retroviruses (lentiviruses) in the pathogenesis of AIDS encephalopathy.

Entities:  

Mesh:

Year:  1986        PMID: 3537646     DOI: 10.1016/0306-9877(86)90065-4

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  5 in total

1.  Persistence of encephalitogenic arboviruses in brain cell culture. Brief report.

Authors:  S Amor; H E Webb
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  HIV-1 effects on neuropsychological performance in a resource-limited country, Zambia.

Authors:  Adelina Holguin; Mwanza Banda; Elizabeth J Willen; Costantine Malama; Kaseya O Chiyenu; Victor C Mudenda; Charles Wood
Journal:  AIDS Behav       Date:  2011-11

3.  Motor dysfunction in HIV-infected patients without clinically detectable central-nervous deficit.

Authors:  G Arendt; H Hefter; C Elsing; G Strohmeyer; H J Freund
Journal:  J Neurol       Date:  1990-10       Impact factor: 4.849

4.  Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.

Authors:  P Portegies; J de Gans; J M Lange; M M Derix; H Speelman; M Bakker; S A Danner; J Goudsmit
Journal:  BMJ       Date:  1989-09-30

5.  Tissue-specific HIV-1 infection: why it matters.

Authors:  Maile Ay Karris; Davey M Smith
Journal:  Future Virol       Date:  2011-07       Impact factor: 1.831

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.